Preview

Научно-практическая ревматология

Расширенный поиск

Аминохинолиновые препараты в терапии системной красной волчанки и антифосфолипидного синдрома

https://doi.org/10.14412/1995-4484-2008-537

Полный текст:

Список литературы

1. <div><p>Иванова А. В. Полякова А. Г. К клинике и лечению системной красной волчанки. Тер. архив. 1961, 4, 65-71.</p><p>Клинические рекомендации. Ревматология. Под ред. Е. Л. Насонова. М., ГЭОТАР-Медиа, 2005. 141-167.</p><p>Муравьев Ю. В., Тургиева Э. П. Терапия антима- лярийными (аминохинолиновыми) препаратами и безопасность органа зрения. Научно-практич. ревматол., 2002, 2, 14-16.</p><p>Насонова В. А. Системная красная волчанка. М. Медицина, 1972, 205-206.</p><p>Рациональная фармакотерапия ревматических заболеваний. Руководство для практикующих врачей. Под ред. В. А. Насоновой, Е. Л. Насонова. М., «Литтерра», 2003, 176.</p><p>Alarcon G. S., McGwin G., Bertoli A. M. el al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis., 2007, 66, 1168-1172.</p><p>Andrade R. М., Alarcon G. S., Gonzalez L. A. et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LfV). Ann. Rheum. Dis., 2007, 17, [Epub. Ahead of print],</p><p>Borba E. F., Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol., 2001, 28, 780-785.</p><p>Callen J. P. Management of skin disease in patients with lupus erythematosus. Best Pract. Res. Clin. Rheumatol., 2002, 16(2), 245-264.</p><p>Christiansen J. V., Nielsen J. P. Treatment of lupus erythematosus with mepacrine: results and relapses during a long observation. Br. J. Dermatol., 1956, 68, 73-87. //. Clowse М. E., Magder L., Witter F., Petri M. Hydroxychloroquine in lupus pregnancy. Arthr. Rheum., 2006, 54(11), 3640-3647.</p><p>Costedoat-Chalumeau N., Amoura Z., Ни lot J. S. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthr. Rheum., 2006, 54(10), 3284-3290.</p><p>Costedoat-Chalumeau N. Amoura Z., Hulot J. S. et al. Very’ low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis., 2007, 66(6), 821-824.</p><p>Costedoat-Chalumeau N., Hulot J. S., Amoura Z. et a I. Heart conduction disorders related to antima- larials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford), 2007, 46 (5), 808-810.</p><p>Edwards М. H., Pierangeli S. S., Liu J. H. et al. Hydroxychloroquine reverses thrombogenic pmperties of antiphospholipid antibodies in mice. Circulation, 1997, 96, 4380-4384.</p><p>Erkan D., Yazici Y., Peterson M. G. et al. A crosssectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology, 2002, 41, 924-929.</p><p>Espinola R. G., Pierangeli S. S., Gharavi A. E., Harris E. N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost., 2002, 87, 518-522.</p><p>Fessler B.Alarcon G. S., McGwin G. et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthr. Rheum., 2005, 52, 1473-1480.</p><p>Fox R. Antimalarial drugs. Mechanisms of action in autoimmune disease and prospects for drug development. Clin. Immunother., 1995, 4, 1-16.</p><p>Fox R. I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthr. Rheum., 1993, 23, 82-91.</p><p>Hansen E. H., Jessing P., Lindewald H. et a I. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine. J. Bone Joint Sutg. Am., 1976, 58, 1089-1093.</p><p>Но К. Т., Ahn C. W, Alarcon G. S. et a I. Systemic lupus erythematosus in a multiethnic cohort (LUMINA XXVIII): Factors predictive of thrombotic events. Rheumatology, 2005, 44, 1303-1307.</p><p>James J. A., Kim-Howard X. R., Bruner B. F. et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus, 2007, 16, 401-409.</p><p>Kasitanon N. Fine D. М., Haas M. et al. Hydroxychloroquine use predicts complete renal remission 12 months among patients treated with mycophe- nolate mofetil therapy for membranous lupus nephritis. Lupus, 2006, 15, 366-370.</p><p>Klinger G., Morad Y., Westall C. A. etal. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet, 2001, 358, 813-814.</p><p>Leadbetter E. A., Rifkin 1. R., Hohlbaum A. M. et al. Chromatin-IgG complexes activate В cells by dual engagement of IgM and ToII-liIce receptors. Nature, 2002, 416, 603-607.</p><p>Levy R. A., Vilela V. S., Cataldo M. J. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled studv. Lupus, 2001, 10(6), 401-404.</p><p>Lopez P., Gomez J., Moz.o L. etal. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthr. Res. Ther., 2006, 8, R42.</p><p>Means Т. K., Latz E., Hayashi F. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR 9. J. Clin. Invest., 2005, 115, 407-417.</p><p>MokC. C., TangS. S. К, ToC. H., Petri M. Incidence and risk factors of thromboembolism in systemic lupus eiythematosus. A comparison of three ethnic groups. Arthr. Rlteum., 2005, 52, 2774-2782.</p><p>Motta М., Tincani A., Faden D. et al. Antimalarial agents in pregnancy. Lancet, 2002, 359, 524-525.</p><p>Muslimani A. A., Spiro T. P., Chaudhry A. A., Daw H. A. Secondary myelodysplastic syndrome after hydroxychloroquine therapy. Ann. Haematol., 2007, 86 (7), 531-534.</p><p>Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus, 1996, 5, 16-22.</p><p>Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol., 1996, 25, 191-193.</p><p>Petri М., Hochberg М., HeUmann D. et al. Incidence and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthr. Rheum., 1992, 35,</p><p>'</p><p>Petri М., Lakatta C., Magder L., Goldman D. W. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med., 1994, 96, 254-259.</p><p>Powrie J. K., Shojaee-Maradie F., Watts G. F. et al. Effects of chloroquine on the dyslipidemia ofnon-insu- line-dependent diabetes me I lit us. Metabolism, 1993, 42, 415-419.</p><p>Roman M. J., Shanker B. A., Davis A. etal. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med., 2003, 349, 2399-2406.</p><p>Ruiz-Irastorza G., Egurbide М. -V, Pijoan J. -I. et al. Effect of antimalarials of thrombosis and survival in patients with systemic lupus erythematosus. Lupus, 2006, 15, 577-583.</p><p>Riither K., Foerster J., Berndt S., Schroeter J. Chloroquine/hydroxychloroquine: variability of reti- notoxic cumulative doses. Ophthalmologe, 2007, 104, 875-880.</p><p>Rynes R. I. Antimalarial drugs in the treatment of rheumatological diseases. Br. J. Rheumatol., 1997,36, 799-805.</p><p>Sato E. 1. Advances in treatment of cutaneous lesions in patients with lupus erythematosus. Lupus, 2007, 16, 37-38.</p><p>Tam L. S., Gladman D., Hallett D. et al. Effect of anti- malarial agents on the fasting lipid profile in systemic lupus erythematosus. J. Rheumatol, 2000, 27, 21422145.</p><p>The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med., 1991, 324, 150-154.</p><p>Tsakonas £., Joseph L., Esdaile J. M. et al. The Canadian hydroxychloroquine study group. A longterm study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus, 1998, 7, 80-85.</p><p>Wallace D. J. Does hydroxychloroquine sulfate prevent dot formation in systemic lupus erythematosus? Arthr. Rheum., 1987, 30, 1435-1436.</p><p>Wallace D. J., Linker-Israeli М., Metzger A. L., Stecher V. J. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus, 1993, 2, 13-15.</p><p>Wallace D. J., Metzger A. L., Steicher V. J. et al. The cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipid. Am. J. Med., 1990, 89, 322326.</p><p>WozjniackaA., Carter A., McCauliffeD. P. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus, 2002, 11, 71-81.</p><p>Ziff М., Esserman P., McEwen C. Observation on the course an treatment of systemic lupus erythematosus, Arthr. Rheum., 1958, 1, 332.</p></div><br />


Для цитирования:


Кондратьева Л.В., Решетняк Т.М. Аминохинолиновые препараты в терапии системной красной волчанки и антифосфолипидного синдрома. Научно-практическая ревматология. 2008;46(4):58-64. https://doi.org/10.14412/1995-4484-2008-537

For citation:


Kondratyeva L.V., Reshetnyak T.M. Aminoquinoline drugs in the treatment of systemic lupus erythematosus and antiphospholipid syndrome. Rheumatology Science and Practice. 2008;46(4):58-64. (In Russ.) https://doi.org/10.14412/1995-4484-2008-537

Просмотров: 1333


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)